Recurrent Pericarditis
May 12, 2023
Daily Download
RA Flares: Management and Risks
May 03, 2023
Women in Academia: The Stats
Apr 25, 2023
2 slides from the AAMC about the role of women in academia and specialties
Private Practice vs Academic Medicine
Apr 19, 2023
The pros and cons of Private Practice vs. Academic Medicine. - submitted by Kathryn Dao, MD
Workforce Shortage
Apr 10, 2023
Gender Risk in Rheumatic Disease
Apr 03, 2023
The risk of autoimmunity and rheumatic disease is heightened in women, especially with aging and certain populations
VTE Risks and JAK inhibition
Mar 13, 2023
Comparing ACR21 vs EULAR22 RA Guidelines
Feb 22, 2023
Distinguishing features between the 2021 ACR and 2022 EULAR RA treatment guidelines
Oral Surveillance - Issues for Clinic
Jan 31, 2023
SLE - New Drug Development
Jan 06, 2023
GCA and PMR New Drugs
Dec 14, 2022
JAKi Regulatory Decisions - FDA, EMA, Canada
Nov 15, 2022
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).